Interim Report for the period October – December 2021

A time of hope for Alzheimer’s patientsEvents during the fourth quarter 2021 · Lecanemab was granted Fast Track designation by the US Food and Drug Administration (FDA), which is a program that is intended to support and expedite the development of new treatments for serious illnesses with significant medical need, such as Alzheimer’s disease. · The clinical section and proposed label, the second of three parts in the rolling submission for lecanemab under the accelerated approval pathway, was submitted to the FDA. · BioArctic announced that the company’s ND3014 drug project is